Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 281 - 288 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC1983 | Tamibarotene |
|
Retinoic acid receptor <span class='symbol'>α</span> (RAR<span class='symbol'>α</span>) agonist that induces differentiation (ED<sub>50</sub> = 0.79 nM) and apoptosis of HL-60 cells <em>in vitro</em>. Exhibits antiproliferative effects against a variety of human tumor cells lines (mean values of 35, 40 and 60% growth inhibition at 0.1, 1 and 10 <span class='symbol'>μ</span>M respectively) and displays anticancer activity against acute promyelocytic leukemia <em>in vivo</em>.
|
|
| BCC1988 | TBB |
|
A cell-permeable, selective inhibitor of casein kinase-2 (CK2) (IC<sub>50</sub> = 0.9 and 1.6 <span class='symbol'>μ</span>M for rat liver and human recombinant CK2 respectively). Exhibits modest discrimination between CK2 subunits, with K<sub>i</sub> values ranging from 80 nM to 210 nM. Acts in an ATP/GTP-competitive manner and displays one to two orders of magnitude selectivity over a panel of 33 protein kinases.
|
|
| BCC1990 | Tedizolid |
|
Torezolid (also known as TR-701 and now tedizolid) is an oxazolidinone antibiotic drug.
|
|
| BCC2000 | Tiotropium Bromide |
|
Potent muscarinic receptor antagonist. Inhibits electrical field stimulation-induced contraction of guinea pig trachea <em>in vitro</em> (IC<sub>50</sub> = 0.17 nM). Induces smooth muscle relaxation and bronchodilation.
|
|
| BCC2005 | Toceranib |
|
Potent ATP-competitive PDGFR and VEGFR inhibitor (K<sub>i</sub> = 5 and 6 nM, respectively); inhibits phosphorylation of c-Kit and suppresses the growth of mast cell lines expressing mutant Kit, inducing cell cycle arrest and apoptosis. Also inhibits FGFR1 (K<sub>i</sub> = 0.5 <span class='symbol'>μ</span>M). Effective <em>in vivo</em>.
|
|
| BCC2016 | Troglitazone |
|
Selective PPAR<span class='symbol'>γ</span> receptor agonist (EC<sub>50</sub> values are 780 and 555 nM at murine and human PPAR<span class='symbol'>γ</span> receptors respectively). Displays no activity at PPAR<span class='symbol'>α</span> or PPAR<span class='symbol'>δ</span> receptors. Antidiabetic agent; exerts potent glucose-lowering effects in insulin-resistant diabetic mice. Displays anti-invasive effect on human breast cancer cells; reduces migration, adhesion and spreading on fibronectin-coated plates. Also inhibits cell growth of hematopoietic cell lines. Inhibits lamellipodia formation and actin polymerization.
|
|
| BCC2017 | TTP 22 |
|
High affinity, ATP-competitive casein kinase 2 (CK2) inhibitor (IC<sub>50</sub> = 0.1 <span class='symbol'>μ</span>M, K<sub>i</sub> = 40 nM). Displays selectivity for CK2 over JNK3, ROCK1 and MET (no inhibitory effects at 10 <span class='symbol'>μ</span>M).
|
|
| BCC2021 | UK-5099 |
|
Inhibitor of plasma membrane monocarboxylate transporters (MCTs) and the mitochondrial pyruvate carrier (MPC).
|
|